Nextbiomedical KRX:389650KOSDAQ
넥스트바이오메디컬 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days0
Articles tracked8since Sep 11
In Q2 2026, Nextbiomedical reported revenue of ₩4.9bn, up 24.3% year on year, and an operating loss of ₩1.0bn. Nextbiomedical (넥스트바이오메디컬) appeared in 1 Korean news article and 0 DART filings over the past seven days. Coverage peaked on Oct 30 with 1 article. The most common catalyst was policy & overseas (1).
Filing signals Swung to loss Screener
Nextbiomedical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩4.9bn | +24.3% | −₩1.0bn margin −20.9% | −₩633m |
| Q1 2026 | ₩4.1bn | +9.2% | −₩1.2bn margin −28.9% | −₩146m |
| Q4 2025 derived | ₩3.8bn | +70.6% | −₩442m margin −11.6% | −₩50m |
| Q3 2025 | ₩4.9bn | +125.1% | ₩370m margin 7.5% | ₩1.1bn |
| Q2 2025 | ₩4.0bn | +44.2% | ₩21m margin 0.5% | −₩902m |
| Q1 2025 | ₩3.8bn | +59.2% | −₩668m margin −17.7% | −₩421m |
| Q4 2024 derived | ₩2.2bn | +56.9% | −₩1.1bn margin −50.0% | ₩144m |
| Q3 2024 | ₩2.2bn | +121.3% | −₩1.0bn margin −46.0% | −₩1.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Nextbiomedical top stories 2 weeks, by number of outlets
- 1